Last reviewed · How we verify

Intranasal Paracetamol

Bezmialem Vakif University · Phase 3 active Small molecule

Intranasal paracetamol inhibits cyclooxygenase enzymes in the central nervous system to reduce pain and fever perception.

Intranasal paracetamol inhibits cyclooxygenase enzymes in the central nervous system to reduce pain and fever perception. Used for Acute pain management, Fever reduction.

At a glance

Generic nameIntranasal Paracetamol
SponsorBezmialem Vakif University
Drug classAnalgesic and antipyretic (non-NSAID)
TargetCyclooxygenase (COX) enzymes
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Paracetamol (acetaminophen) is a non-selective inhibitor of cyclooxygenase (COX) enzymes, primarily acting in the brain and spinal cord to suppress prostaglandin synthesis. The intranasal formulation delivers the drug directly to nasal mucosa for rapid systemic absorption, potentially providing faster onset of analgesic and antipyretic effects compared to oral administration. This route bypasses first-pass hepatic metabolism to some degree, potentially allowing lower doses to achieve therapeutic effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: